Cytokinetics (NASDAQ:CYTK) Selects For Addition To S&P SmallCap 600 GICS Biotechnology Sub-Industry Index
Cytokinetics, Incorporated (NASDAQ:CYTK) shares price shows upbeat performance moved up 5.17% during last trading session. Cytokinetics (CYTK) released that it has been selected for addition to the S&P SmallCap 600 GICS Biotechnology Sub-Industry Index. The index, a member of the Dow Jones Total Stock Market Indices family, is designed to measure the performance of small-cap U.S. equity securities.
CYTK revolves under ordinary profitability ratio, it has operating margin is calculated as 17.50% for trailing twelve months. The returns on investment strengthen findings as Cytokinetics, Incorporated (NASDAQ:CYTK)’s ROI calculated as 15.00%; which gives idea about efficiency of different investments. Also noticeable think is returns on assets that stand at 12.00%, it indicates how profitable a firm is relative to its total assets.
Cytokinetics, Incorporated (NASDAQ:CYTK) has price to book ratio of 6.12 and price to earnings ratio of 43.31, which is valid method to judge except not universal for all situation. Moving toward ratio analysis, the firm has price to earnings ratio of 43.31. The price to earnings growth rations stands at 2.89. The co is presenting price to cash flow as 3.83 and while calculating price to free cash flow it concluded at 16.92, low single digit might indicate stock is undervalued and vice versa.
To identify firm has sufficient short-term assets to cover its immediate liabilities, we look on Quick Ratio that stands at 4.80. The firm has price volatility of 4.82% for a week and 4.48% for a month. Cytokinetics, Incorporated (NASDAQ:CYTK) has debt to equity ratio of 0.32, most of the time it remain equal with long term debt to equity ratio. As look on its weekly performance, it has 22.84% and monthly performance was 11.33%.